Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

3'-deamino-3'-hydroxydoxorubicin

Known as: 3-DHD, 5,12-Naphthacenedione, 10-((2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, hydroxyrubicin 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
2001
2001
Cells that acquire multidrug resistance (MDR) are characterized by a decreased accumulation of a variety of drugs. In addition… Expand
Highly Cited
2000
Highly Cited
2000
Multidrug resistance phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or Multidrug… Expand
Highly Cited
1997
Highly Cited
1997
The knowledge about molecular factors driving simple ligand-DNA interactions is still limited. The aim of the present study was… Expand
1994
1994
Hydroxyrubin (OH‐Dox), a neutral doxorubicin derivative that is only slightly cross‐resistant to doxorubicin (Dox), can be… Expand
1994
1994
In vivo effectiveness of doxorubicin remains restricted due to toxicity and drug resistance. Hydroxyrubicin is a synthetic analog… Expand
Highly Cited
1993
Highly Cited
1993
Hydroxyrubicin, a synthetic doxorubicin analog in which the basic amino group at C-3' is replaced by a hydroxyl group, was used… Expand
1993
1993
Results presented in this study indicate that monensin, a Na+/H+ gradient ionophore, is by itself a potent inhibitor of… Expand
1984
1984
3'-Deamino-4'-epi-3'-hydroxy-daunorubicin (11) and -doxorubicin (14) have been synthesized. In the in vivo murine P-388… Expand
1984
1984
Two successful routes have been developed for preparation of 3'-deamino-3'-hydroxydoxorubicin (11), based on protection of the 14… Expand
  • table 1